Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.290
-0.070-2.97%
Volume:1.42M
Turnover:3.28M
Market Cap:2.97B
PE:-36.98
High:2.345
Open:2.320
Low:2.280
Close:2.360
52wk High:3.310
52wk Low:1.880
Shares:1.30B
Float Shares:786.49M
Volume Ratio:0.80
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.062
EPS(LYR):-0.062
ROE:-9.86%
ROA:-4.11%
PB:3.75
PE(LYR):-36.98

Loading ...

Mesoblast Posts Ryoncil Q4 Net Revenue of $36M

Reuters
·
Jul 10

Ryoncil® Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026

THOMSON REUTERS
·
Jul 10

Press Release: Ryoncil(r) Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026

Dow Jones
·
Jul 10

Mesoblast Ltd - Ryoncil Q4 Net Revenue of Us$36m and Us$115m for Full Year

THOMSON REUTERS
·
Jul 10

3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now

Simply Wall St.
·
Jul 09

3 Australian Founder Led Stocks With Long Term Skin In The Game

Simply Wall St.
·
Jul 07

Mesoblast Requests Modular Review of BLA for Rexlemestrocel-l in End-stage Heart Failure with LVAD

Reuters
·
Jul 06

3 Founder Led ASX Stocks Retail Investors Are Watching For Management Alignment

Simply Wall St.
·
Jul 06

Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L

Simply Wall St.
·
Jul 04

Founder Led Stocks Retail Investors Are Watching In Australia Right Now

Simply Wall St.
·
Jul 02

Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?

Simply Wall St.
·
Jul 02

Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy

Stock Track
·
Jul 01

Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%

MT Newswires Live
·
Jul 01

Mesoblast Wins FDA BLA Filing Number for Rexlemestrocel-l, Seeks Modular Review in LVAD Patients

Reuters
·
Jul 01

Mesoblast - Requests Modular Review of Bla for Rexlemestrocel-l in End-stage Heart Failure with Lvad

THOMSON REUTERS
·
Jul 01

Mesoblast - Rexlemestrocel-l Receives Orphan Drug and Rmat Designations

THOMSON REUTERS
·
Jul 01

Founder Led Stocks With Long Term Skin In The Game

Simply Wall St.
·
Jul 01

3 Founder Led Australian Stocks With Insider Skin In The Game

Simply Wall St.
·
Jun 29

Founder Led Stocks Why Investors Are Looking At Flight Centre And 2 More

Simply Wall St.
·
Jun 28

3 Promising ASX Penny Stocks With Over A$60M Market Cap

Simply Wall St.
·
Jun 26